Literature DB >> 31065757

Concurrent Use of Calcium Chloride and Arginine Vasopressin Infusions in Pediatric Patients with Acute Cardiocirculatory Failure.

Karan B Karki1, Jeffrey A Towbin2, Camden Harrell3, James Tansey4, Joseph Krebs4, William Bigelow4, Arun Saini5, Sachin D Tadphale6,7.   

Abstract

Acute heart failure (AHF) can cause low cardiac output and poor end-organ perfusion. Inotropic agents along with vasodilators can improve organ perfusion. Arginine vasopressin (AVP) and calcium chloride (CaCl) infusions are increasingly being used in low cardiac output states in pediatric AHF. We retrospectively reviewed 77 patients (0-18 years) with AHF admitted between January 2014 and May 2017 who received concurrent AVP and CaCl infusions. Surrogates of cardiac output and organ perfusion included hemodynamic vital signs, laboratory parameters, and urine output (UO). Organ dysfunction and vasopressor inotropic scores were also calculated. Median (IQR) age was 0.88 years (0, 3.75), and median weight was 6.62 kg (3.5, 13.7). Congenital heart disease was present in 70% (46/77) patients. Univentricular physiology was present in 25% (25/77) patients. None of the patients were in the immediate postoperative period. Median durations of AVP and CaCl were 2 days (1, 3) and 3 days (2, 6), respectively. Using Wilcoxon-signed rank test and Bonferroni correction, post hoc comparison showed that at 8 h post infusion, all systolic blood pressure (SBP) and diastolic blood pressure (DBP) results, and UO were greater than those 1 h prior to infusion. Median SBP increased from 79 mm Hg (71, 92) 1 h prior to 97 mm Hg (84, 107) 8 h post. Median DBP increased from 44 mm Hg (35, 52) 1 h prior to 54 mm Hg (44, 62) 8 h post. Heart rate showed a decrease between measurements 1 h prior to infusion and 8 h post, with median scores 146 (127, 162) and 136 (114, 150) beats per minute, respectively. Within first 8 h, median UO continuously increased from 6 mL/h. (0, 25) at 1 h post infusion to 20 mL/h. (2, 62) at 8 h post infusion. Median pediatric logarithmic organ dysfunction scores on days 4 through 7 post infusion were lower compared to day 1; median vasopressor inotropic scores on day 2 through 7 post infusion were lower compared to day 1. Serum lactate level, arterial pH, and base excess all showed favorable trend. Concurrent use of AVP and CaCl infusions may improve surrogates of cardiac output, and intensive care outcomes, and prevent organ dysfunction in children with AHF.

Entities:  

Keywords:  Acute cardiocirculatory failure; Acute decompensated heart failure; Calcium; Congenital heart disease; Pediatric heart failure; Vasopressin

Mesh:

Substances:

Year:  2019        PMID: 31065757     DOI: 10.1007/s00246-019-02114-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  38 in total

1.  Development of a pediatric multiple organ dysfunction score: use of two strategies.

Authors:  S Leteurtre; A Martinot; A Duhamel; F Gauvin; B Grandbastien; T V Nam; F Proulx; J Lacroix; F Leclerc
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

Review 2.  Adrenergic overload and apoptosis in heart failure: implications for therapy.

Authors:  W S Colucci; D B Sawyer; K Singh; C Communal
Journal:  J Card Fail       Date:  2000-06       Impact factor: 5.712

Review 3.  Cellular and molecular aspects of myocardial dysfunction.

Authors:  S M Schwartz; J Y Duffy; J M Pearl; D P Nelson
Journal:  Crit Care Med       Date:  2001-10       Impact factor: 7.598

4.  Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure.

Authors:  A Eisenman; Z Armali; R Enat; L Bankir; Y Baruch
Journal:  J Intern Med       Date:  1999-08       Impact factor: 8.989

5.  Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries.

Authors:  T Okamura; K Ayajiki; H Fujioka; N Toda
Journal:  J Hypertens       Date:  1999-05       Impact factor: 4.844

Review 6.  Adrenergic regulation of myocardial apoptosis.

Authors:  K Singh; C Communal; D B Sawyer; W S Colucci
Journal:  Cardiovasc Res       Date:  2000-02       Impact factor: 10.787

7.  A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass.

Authors:  David L S Morales; Mauricio J Garrido; John D Madigan; David N Helman; Joseph Faber; Mathew R Williams; Donald W Landry; Mehmet C Oz
Journal:  Ann Thorac Surg       Date:  2003-03       Impact factor: 4.330

8.  Cardiac performance during vasopressin infusion in postcardiotomy shock.

Authors:  M W Dünser; A J Mayr; A Stallinger; H Ulmer; N Ritsch; H Knotzer; W Pajk; N J Mutz; W R Hasibeder
Journal:  Intensive Care Med       Date:  2002-04-30       Impact factor: 17.440

9.  Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study.

Authors:  Stéphane Leteurtre; Alain Martinot; Alain Duhamel; François Proulx; Bruno Grandbastien; Jacques Cotting; Ronald Gottesman; Ari Joffe; Jurg Pfenninger; Philippe Hubert; Jacques Lacroix; Francis Leclerc
Journal:  Lancet       Date:  2003-07-19       Impact factor: 79.321

10.  Multiple organ dysfunction syndrome in children.

Authors:  José A Tantaleán; Rosa J León; Alejandro A Santos; Eduardo Sánchez
Journal:  Pediatr Crit Care Med       Date:  2003-04       Impact factor: 3.624

View more
  2 in total

Review 1.  Impact of Medical Interventions and Comorbidities on Norwood Admission for Patients with Hypoplastic Left Heart Syndrome.

Authors:  Rohit S Loomba; Jacqueline Rausa; Juan S Farias; Enrique G Villarreal; Sebastian Acosta; Fabio Savorgnan; Saul Flores
Journal:  Pediatr Cardiol       Date:  2022-01-15       Impact factor: 1.655

2.  A retrospective analysis of calcium levels in pediatric trauma patients.

Authors:  Brian G Cornelius; Daniel Clark; Ben Williams; Anna Rogers; Andreea Popa; Phillip Kilgore; Urska Cvek; Marjan Trutschl; Kevin Boykin; Angela Cornelius
Journal:  Int J Burns Trauma       Date:  2021-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.